MDM2 (12q15) Amplification, Well-Differentiated Liposarcoma/Atypical Lipomatous Tumor, FISH, Tissue
The MDM2 gene, located at chromosome band 12q15, encodes an E3 ubiquitin ligase that acts as a key negative regulator of the tumor suppressor TP53 (p53). MDM2 promotes ubiquitination and proteasomal degradation of p53, thereby inhibiting p53-mediated cell cycle arrest and apoptosis. Amplification and overexpression of MDM2 allow tumor cells to bypass p53-dependent growth control without requiring mutations in the TP53 gene. Although MDM2 amplification is present in a relatively small percentage of human malignancies overall, it is a defining molecular feature of well-differentiated liposarcoma (WDL) and atypical lipomatous tumor (ALT), as well as dedifferentiated liposarcoma.
WDL/ALT represents a group of locally aggressive adipocytic neoplasms that most commonly arise in deep soft tissues of the extremities, retroperitoneum, or paratesticular region, typically in middle-aged to older adults. These tumors often resemble benign lipomas or other adipocytic lesions on histology, particularly in small biopsies, creating significant diagnostic challenges. Dedifferentiated liposarcoma may additionally mimic high-grade sarcomas. Cytogenetically, these tumors are characterized by amplification of the 12q13–15 chromosomal region, including MDM2 and frequently CDK4, often present on supernumerary ring or giant marker chromosomes.
Fluorescence in situ hybridization (FISH) for MDM2 amplification is a well-established ancillary diagnostic tool that enables reliable distinction of WDL/ALT and dedifferentiated liposarcoma from benign lipomatous tumors and histologic mimics. Dual-color MDM2/CEP12 FISH performed on formalin-fixed paraffin-embedded tissue provides high sensitivity and specificity and is particularly valuable when morphology and immunohistochemistry are equivocal or when conventional karyotyping is not feasible.
- Helpful in the diagnosis of Well Differentiated Liposarcoma / Atypical Lipomatous Tumor
- Helps distinguish WDL/ALT and dedifferentiated liposarcoma from benign lipomas and other adipocytic neoplasms
- Useful in the evaluation of parosteal osteosarcoma and low-grade central osteosarcoma, which may also demonstrate MDM2 amplification
A positive result is defined by detection of MDM2 gene amplification, demonstrated by an increased MDM2 to chromosome 12 centromere (CEP12) signal ratio or high-level polysomy exceeding established laboratory cutoffs. In the appropriate clinical and histopathologic context, this finding supports a diagnosis of WDL/ALT, dedifferentiated liposarcoma, or other MDM2-amplified tumors such as parosteal or low-grade central osteosarcoma.
A negative result indicates absence of detectable MDM2 amplification. This finding argues against WDL/ALT but does not entirely exclude the diagnosis, particularly in cases with sampling limitations or technical factors. Final diagnosis should integrate molecular findings with histologic features, imaging studies, and clinical information.
Negative no MDM2 amplification. Results are reported qualitatively with interpretive comments
Tissue, Fresh frozen paraffin embedded (FFPE).
Stable at room temperature for long time.
- Hum Pathol. 2024 May;147:82-91. [PMID: 38135062]
- Diagnostics (Basel). 2021 Mar 11;11(3):496. [PMID: 33799733]
- Mod Pathol. 2008 Aug;21(8):943-9. [PMID: 18500263]
- Appl Immunohistochem Mol Morphol. 2015 Feb;23(2):126-33. [PMID: 25679065]